BALANCE 2,3 % GLÜKOOS, 1,75 MMOL/L KALTSIUM peritoneaaldialüüsilahus Estonja - Estonjan - Ravimiamet

balance 2,3 % glükoos, 1,75 mmol/l kaltsium peritoneaaldialüüsilahus

fresenius medical care deutschland gmbh - hüpertoonilised lahused - peritoneaaldialüüsilahus - 6000ml 2tk

BALANCE 4,25 % GLÜKOOS, 1,75 MMOL/L KALTSIUM peritoneaaldialüüsilahus Estonja - Estonjan - Ravimiamet

balance 4,25 % glükoos, 1,75 mmol/l kaltsium peritoneaaldialüüsilahus

fresenius medical care deutschland gmbh - hüpertoonilised lahused - peritoneaaldialüüsilahus - 2500ml 4tk; 5000ml 2tk; 3000ml 4tk; 6000ml 2tk

BALANCE 1,5 % GLÜKOOS, 1,75 MMOL/L KALTSIUM peritoneaaldialüüsilahus Estonja - Estonjan - Ravimiamet

balance 1,5 % glükoos, 1,75 mmol/l kaltsium peritoneaaldialüüsilahus

fresenius medical care deutschland gmbh - hüpertoonilised lahused - peritoneaaldialüüsilahus - 3000ml 4tk; 5000ml 2tk

BALANCE 2,3 % GLÜKOOS, 1,25 MMOL/L KALTSIUM peritoneaaldialüüsilahus Estonja - Estonjan - Ravimiamet

balance 2,3 % glükoos, 1,25 mmol/l kaltsium peritoneaaldialüüsilahus

fresenius medical care deutschland gmbh - hüpertoonilised lahused - peritoneaaldialüüsilahus - 5000ml 2tk

Vazkepa Unjoni Ewropea - Estonjan - EMA (European Medicines Agency)

vazkepa

amarin pharmaceuticals ireland limited - icosapent ethyl - düslipideemiad - lipiidi modifitseerivad ained - indicated to reduce cardiovascular risk as an adjunct to statin therapy.

Tavneos Unjoni Ewropea - Estonjan - EMA (European Medicines Agency)

tavneos

vifor fresenius medical care renal pharma france - avacopan - microscopic polyangiitis; wegener granulomatosis - immunosupressandid - tavneos, in combination with a rituximab or cyclophosphamide regimen, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (gpa) or microscopic polyangiitis (mpa).

CIGENTA infusioonilahus Estonja - Estonjan - Ravimiamet

cigenta infusioonilahus

fresenius medical care deutschland gmbh - naatriumtsitraat - infusioonilahus - 136mmol 1l 1500ml 8tk

Kapruvia Unjoni Ewropea - Estonjan - EMA (European Medicines Agency)

kapruvia

vifor fresenius medical care renal pharma france - difelikefalin - pruritus - kõik muud ravitoimingud - kapruvia is indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult patients on haemodialysis (see section 5.

Steglatro Unjoni Ewropea - Estonjan - EMA (European Medicines Agency)

steglatro

merck sharp & dohme b.v. - ertugliflozin l-pyroglutamic happega - suhkurtõbi, tüüp 2 - drugs used in diabetes, sodium-glucose co-transporter 2 (sglt2) inhibitors - steglatro on näidustatud täiskasvanutel vanuses 18 aastat ja vanemad, tüüp 2 diabeet lisandina toitumise ja treeningu parandamiseks glycaemic kontroll:kui monotherapy patsientidel, kellele kasutamise metformiin on ebasobivaks, kuna talumatus või vastunäidustused. lisaks teiste ravimitega ravi diabeet.

Segluromet Unjoni Ewropea - Estonjan - EMA (European Medicines Agency)

segluromet

merck sharp & dohme b.v. - ertugliflozin l-pyroglutamic acid, metformin hydrochloride - suhkurtõbi, tüüp 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - segluromet is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:in patients not adequately controlled on their maximally tolerated dose of metformin alonein patients on their maximally tolerated doses of metformin in addition to other medicinal products for the treatment of diabetesin patients already being treated with the combination of ertugliflozin and metformin as separate tablets.